Showing results (441-450 of 661) with videos related to

Sort By:
Pageof 67
Cancer Biotherapy & Radiopharmaceuticals|April 22, 2021
227Th-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed/Refractory CD22-Positive Non-Hodgkin Lymphoma: A First-in-Human, Phase I StudyOla Lindén, Andrew T Bates, David Cunningham, et al.
Cancer Discovery|February 8, 2020
Pan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma CancersVivek Subbiah, Igor Puzanov, Jean-Yves Blay, et al.
BMJ Open|February 8, 2020
NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)Zoe Craig, Jayne Swain, Emma Batman, et al.
Journal of Gastroenterology and Hepatology|September 30, 2017
Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOWKei Muro, Jae Yong Cho, Gyorgy Bodoky, et al.
European Journal of Cancer (Oxford, England : 1990)|August 20, 2013
A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO)Gary Middleton, Sarah Brown, Catherine Lowe, et al.
Clinical Pharmacokinetics|September 6, 2015
Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic MalignanciesElodie Odore, François Lokiec, Esteban Cvitkovic, et al.
World Journal of Nuclear Medicine|July 22, 2022
The Diagnostic Accuracy of 18 F-FGD-PET/CT for Cancer of the Gallbladder: A Retrospective StudyStephanos Pericleous, Sophie L F Doran, Andrew Wotherspoon, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|June 28, 2020
Histological intratumoral heterogeneity in pretreatment esophageal cancer biopsies predicts survival benefit from neoadjuvant chemotherapy: results from the UK MRC OE02 trialNaser Davarzani, Lindsay C Hewitt, Matthew D Hale, et al.
JAMA Oncology|December 6, 2016
Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical TrialManish A Shah, Yung-Jue Bang, Florian Lordick, et al.
Health Technology Assessment (Winchester, England)|February 4, 2014
The clinical effectiveness and cost-effectiveness of ablative therapies in the management of liver metastases: systematic review and economic evaluationEmma Loveman, Jeremy Jones, Andrew J Clegg, et al.
Pageof 67